Garassino MC, et al. - Durvalumab's (anti-PD-L1) impact was assessed in three cohorts of patients with non-small-cell lung cancer (NSCLC) defined by EGFR/anaplastic lymphoma kinase (ALK) status and tumour expression of PD-L1. Durvalumab showed clinical activity and safety profile that was consistent with that of other anti-PD-1 and anti-PD-L1 agents in patients with advanced and heavily pretreated NSCLC. Higher proportion of patients with EGFR–/ALK– NSCLC (cohorts 2 and 3, NSCLC without EGFR tyrosine kinase or ALK genetic aberrations) achieved a response, relative to those with EGFR+/ALK+ NSCLC (cohort 1, NSCLC with EGFR mutations or ALK rearrangements) achieving a response. The clinical activity of durvalumab in patients with EGFR+ NSCLC with ≥25% of tumour cells expressing PD-L1 was encouraging.